Craven House Capital (GB:CRV) has released an update.
Craven House Capital PLC has received a significant stake in Quiapeg Pharma AB, a drug development company, after its investee company, RoseMonkey Ltd, sold IP rights and completed a financing transaction. Craven House now holds 23.2% of QuiaPeg, valued at approximately $758,792, thanks to RoseMonkey distributing a portion of its newly acquired QuiaPeg shares to its shareholders. This strategic move maintains Craven House’s 24.4% shareholding in RoseMonkey and expands its investment portfolio into the pharmaceutical sector.
For further insights into GB:CRV stock, check out TipRanks’ Stock Analysis page.
